Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME

Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks Inc. (NASDAQ:ZYME) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,022,840 shares of the company’s stock, valued at approximately $26,931,000. Zymeworks makes up about 6.5% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its biggest holding. Capricorn Fund Managers Ltd owned 1.37% of Zymeworks at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC increased its position in shares of Zymeworks by 86.0% in the 1st quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after buying an additional 22,411 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after acquiring an additional 1,427 shares in the last quarter. Jane Street Group LLC grew its stake in Zymeworks by 487.0% in the first quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock valued at $1,617,000 after acquiring an additional 112,636 shares during the period. Creative Planning increased its holdings in shares of Zymeworks by 114.8% in the second quarter. Creative Planning now owns 25,389 shares of the company’s stock worth $319,000 after acquiring an additional 13,567 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Zymeworks by 1,050.0% during the second quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock worth $5,543,000 after purchasing an additional 403,281 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity

In related news, COO Mark Hollywood sold 6,120 shares of Zymeworks stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $138,740.40. Following the completion of the transaction, the chief operating officer owned 132,913 shares in the company, valued at approximately $3,013,137.71. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey T. L. Smith sold 9,310 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $22.67, for a total value of $211,057.70. Following the completion of the sale, the executive vice president owned 26,708 shares in the company, valued at $605,470.36. This represents a 25.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 55,414 shares of company stock worth $1,256,235. Insiders own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ZYME shares. Wells Fargo & Company upgraded Zymeworks from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $25.00 to $33.00 in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, January 21st. Truist Financial began coverage on shares of Zymeworks in a research note on Wednesday, December 17th. They issued a “buy” rating and a $40.00 price target on the stock. Leerink Partners upped their price target on shares of Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Finally, HC Wainwright increased their price objective on shares of Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.89.

Zymeworks Price Performance

ZYME stock opened at $25.80 on Monday. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -23.89 and a beta of 1.20. Zymeworks Inc. has a twelve month low of $9.03 and a twelve month high of $28.49. The business has a 50 day moving average price of $23.66 and a two-hundred day moving average price of $22.48.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.55) EPS for the quarter. The company had revenue of $2.52 million during the quarter. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%.

Zymeworks Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.